Liver enzyme elevations were observed in 4.1% of participants receiving tolebrutinib compared with 1.6% in the placebo group. Friday, Sanofi SA SNY released data from the HERCULES phase 3 study of ...
FRANKFURT (Reuters) - Sanofi said on Friday that its multiple ... this month that the late-stage trial with the drug candidate tolebrutinib was successful. (Reporting by Ludwig Burger; editing ...
Some results have been hidden because they may be inaccessible to you